6533b852fe1ef96bd12ab8f6

RESEARCH PRODUCT

Spectrum of pncA Mutations in Multidrug-Resistant Mycobacterium tuberculosis Isolates Obtained in Latvia

Anda NodievaOlgerts MargaInta JansoneTatjana TracevskaViesturs BaumanisGirts Skenders

subject

TuberculosisAntitubercular AgentsAmidohydrolasesMicrobiologyMycobacterium tuberculosischemistry.chemical_compoundPyrazinoic acidDrug Resistance Multiple BacterialmedicineHumansTuberculosisPharmacology (medical)Multidrug-Resistant Mycobacterium tuberculosisCodonLetters to the EditorPharmacologybiologyReverse Transcriptase Polymerase Chain ReactionMycobacterium tuberculosisPyrazinamidebiology.organism_classificationmedicine.diseaseLatviaPyrazinamideVirologyInfectious DiseaseschemistryMutationPncAmedicine.drug

description

Pyrazinamide (PZA) is an effective antituberculous agent ([1][1]) that becomes active when bacterial pyrazinamidase converts it to pyrazinoic acid, which is toxic to mycobacteria ([4][2]). In Mycobacerium tuberculosis , PZA resistance is associated with the loss of pyrazinamidase activity, mainly

yearjournalcountryeditionlanguage
2004-07-27Antimicrobial Agents and Chemotherapy
https://doi.org/10.1128/aac.48.8.3209-3210.2004